.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Argus Health
McKinsey
Baxter
Fuji
Accenture
Teva
Covington
Boehringer Ingelheim
Dow

Generated: December 13, 2017

DrugPatentWatch Database Preview

FENOFIBRATE - Generic Drug Details

« Back to Dashboard

What are the generic sources for fenofibrate and what is the scope of fenofibrate freedom to operate?

Fenofibrate
is the generic ingredient in nine branded drugs marketed by Lupin Atlantis, Sun Pharm Inds Ltd, Apotex Inc, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Impax Labs, Invagen Pharms, Mylan Pharms Inc, Rhodes Pharms, Abbvie, Cipher Pharms Inc, Aurobindo Pharma Ltd, Cipla Ltd, Hetero Labs Ltd Iii, Lupin Ltd, Mylan, Valeant Pharms North, Santarus Inc, Abbvie Inc, and Skyepharma Ag, and is included in twenty-nine NDAs. There are eighteen patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Fenofibrate has four hundred and seventeen patent family members in forty-nine countries.

There are forty-two drug master file entries for fenofibrate. Fifty-four suppliers are listed for this compound. There is one tentative approval for this compound.

Medical Subject Heading (MeSH) Categories for FENOFIBRATE

Tentative approvals for FENOFIBRATE

Applicant Application No. Strength Dosage Form
u► Subscribe43MGCAPSULE; ORAL
u► Subscribe130MGCAPSULE; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs SaFENOFIBRATE (MICRONIZED)fenofibrateCAPSULE;ORAL090859-002Mar 1, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin LtdFENOFIBRATEfenofibrateTABLET;ORAL204019-001Aug 17, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sun Pharm Inds LtdFENOFIBRATEfenofibrateTABLET;ORAL076635-003Oct 31, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
AbbvieTRICOR (MICRONIZED)fenofibrateCAPSULE;ORAL019304-003Jun 30, 1999DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Cipla LtdFENOFIBRATEfenofibrateTABLET;ORAL208709-002Dec 15, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdFENOFIBRATEfenofibrateTABLET;ORAL205118-002May 5, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Invagen PharmsFENOFIBRATE (MICRONIZED)fenofibrateCAPSULE;ORAL207378-003Mar 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
MylanFENOFIBRATEfenofibrateTABLET;ORAL076520-003Oct 25, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lupin AtlantisANTARA (MICRONIZED)fenofibrateCAPSULE;ORAL021695-005Oct 18, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Mylan Pharms IncFENOFIBRATE (MICRONIZED)fenofibrateCAPSULE;ORAL202579-001Jan 10, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fenofibrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-003Sep 4, 2001► Subscribe► Subscribe
AbbvieTRICORfenofibrateTABLET;ORAL021656-001Nov 5, 2004► Subscribe► Subscribe
AbbvieTRICOR (MICRONIZED)fenofibrateCAPSULE;ORAL019304-002Feb 9, 1998► Subscribe► Subscribe
Lupin AtlantisANTARA (MICRONIZED)fenofibrateCAPSULE;ORAL021695-001Nov 30, 2004► Subscribe► Subscribe
AbbvieLIPIDILfenofibrateCAPSULE;ORAL019304-001Dec 31, 1993► Subscribe► Subscribe
AbbvieTRICOR (MICRONIZED)fenofibrateCAPSULE;ORAL019304-003Jun 30, 1999► Subscribe► Subscribe
Cipher Pharms IncLIPOFENfenofibrateCAPSULE;ORAL021612-001Jan 11, 2006► Subscribe► Subscribe
Lupin AtlantisANTARA (MICRONIZED)fenofibrateCAPSULE;ORAL021695-002Nov 30, 2004► Subscribe► Subscribe
Cipher Pharms IncLIPOFENfenofibrateCAPSULE;ORAL021612-002Jan 11, 2006► Subscribe► Subscribe
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-001Sep 4, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fenofibrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,772,273Stabilized atorvastatin► Subscribe
8,293,277Controlled-release nanoparticulate compositions► Subscribe
7,198,795In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions► Subscribe
7,244,451Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► Subscribe
8,586,094Coated tablets► Subscribe
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► Subscribe
7,927,627Nanoparticulate fibrate formulations► Subscribe
8,703,202Coated tablets► Subscribe
6,811,767 Liquid droplet aerosols of nanoparticulate drugs► Subscribe
8,529,952Pharmaceutical composition containing fenofibrate and method for the preparation thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fenofibrate

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0027363► Subscribe
Estonia200200011► Subscribe
Japan4831965► Subscribe
China1682707► Subscribe
Serbia50035► Subscribe
Japan2010013462► Subscribe
Austria343376► Subscribe
Japan2007508249► Subscribe
Ukraine72925► Subscribe
Canada2582405► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
AstraZeneca
Accenture
Merck
Queensland Health
Federal Trade Commission
Healthtrust
Colorcon
Mallinckrodt
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot